Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipterbin and Vinorelbine in HER2-positive metastatic breast cancer
NCT05131841Phase 4Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of inetetamab in breast cancer, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05131841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131841.